CDK4 and melanoma: Through scRNA-seq analysis on melanoma patients pre- and post-ICB treatment, Jerby-Arnon et al. (2018) identified an ICB resistance program-upregulation of the CDK4/6 pathway by melanoma tumor cells-that led to T cell exclusion and immune evasion.